AstraZeneca’s Imfinzi has been approved in China for the 1st-line treatment of adult patients with locally advanced or metastatic biliary tract cancer, or BTC, in combination with chemotherapy, the company announced. The approval by China’s National Medical Products Administration was based on the primary results from the TOPAZ-1 Phase III trial published in the New England Journal of Medicine Evidence, as well as a prespecified exploratory analysis of an additional cohort of patients in China, AstraZeneca said.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AZN:
- Best Stocks to Buy Now, 11/10/2023, According to Top Analysts
- AstraZeneca: Imfinzi+bevacizumab met primary endpoint for PFS in liver cancer
- Options Volatility and Implied Earnings Moves Today, November 09, 2023
- AstraZeneca announces results from EMERALD-1 Phase III trial of Imfinzi
- AstraZeneca raises FY core EPS view to up low double digits to low teens